Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018. J Clin Oncol. 2018;36 (suppl; abstr 9503).
Toevoegen atezolizumab bij gemetastaseerd, persisterend of gerecidiveerd cervixcarcinoom
mrt 2024 | Gynaecologische oncologie